Although serum VEGF to predict short-term treatment efficacy in ESCC patients had high sensitivity (93.7%), the specificity was low (42.9%), suggesting that it alone is unreliable in predicting short-term efficacy. This evidence concerns the gene VEGFA and esophageal squamous cell carcinoma.